

CLAIMS

1. A method for identifying a subject suffering from, or at risk of suffering from gastric cancer, the method comprises:

- a. detecting the expression level of the miRNA marker combination comprising hsa-miR-29c-3p, hsa-miR-424-5p, hsa-miR-103a-3p, hsa-miR-93-5p, hsa-miR-181a-5p, hsa-miR-21-5p, hsa-miR-140-5p, hsa-miR-30e-5p, hsa-miR-142-5p, hsa-miR-126-3p, hsa-miR-183-5p and hsa-miR-340-5p in a peripheral blood sample obtained from the subject,
- b. calculating the risk score of the subject with the non-cancer control sample as a reference, and
- c. determining the possibility of the subject suffering from, or at risk of suffering from gastric cancer based on the risk score.

2. The method according to claim 1, wherein a linear regression model is used to calculate the risk score.

3. The method according to claim 2, wherein the linear regression model is calculated as follows:

$$\text{Logistic} = (K_{\text{miRNA1}} * \text{Ct}_{\text{miRNA1}}) + (K_{\text{miRNA2}} * \text{Ct}_{\text{miRNA2}}) + (K_{\text{miRNA3}} * \text{Ct}_{\text{miRNA3}}) + \dots + \text{Constant}$$

wherein miRNA1, miRNA2, miRNA3... are selected from the miRNA marker combination according to claim 1; Ct is the relative expression level of each miRNA detected by qPCR; and K is the coefficient of each miRNA marker.

4. The method according to any one of claims 1 to 3, wherein the method comprises a qPCR method, a chip method or a sequencing method for detecting the miRNA marker.

5. A kit for diagnosing gastric cancer, the kit comprises reagents for specifically detecting the miRNA marker combination consisting of hsa-miR-29c-3p, hsa-miR-424-5p, hsa-miR-103a-3p, hsa-miR-93-5p, hsa-miR-181a-5p, hsa-miR-21-5p, hsa-miR-140-5p, hsa-miR-30e-5p, hsa-miR-142-5p, hsa-miR-126-3p, hsa-miR-183-5p and hsa-miR-340-5p.

6. The kit according to claim 5, wherein the reagent comprises at least one oligonucleotide for detecting the miRNA markers in the miRNA marker combination, wherein at least a part of the

oligonucleotide specifically binds to the miRNA markers.

7. The kit according to claim 5 or 6, wherein the kit comprises a stem-loop reverse transcription primer and/or a semi-nested qPCR primer for amplifying each miRNA marker in the miRNA marker combination.